

## *Supporting Info*

# Synthesis, Structural Modification and Bioactivity Evaluation of Substituted Acridones as Potent Microtubule Affinity-Regulating Kinase 4 Inhibitors

Maria Voura,<sup>a</sup> Saleha Anwar,<sup>b</sup> Ioanna Sigala,<sup>c</sup> Eleftheria Parasidou,<sup>a</sup> Souzanna Fragoulidou,<sup>a</sup> Md. Imtaiyaz Hassan<sup>b\*</sup> and Vasiliki Sarli<sup>a\*</sup>

<sup>a</sup> Laboratory of Organic Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124, Thessaloniki, Greece, [sarli@chem.auth.gr](mailto:sarli@chem.auth.gr)

<sup>b</sup> Centre for interdisciplinary research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025, India.

<sup>c</sup> Laboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124, Thessaloniki, Greece.

**Table of contents**

<b>1</b>	Table S1. Docking scores and interactions between MARK4 and synthesized acridones	<b>3</b>
<b>2</b>	Table S2. Druglikeness of synthesized acridones.	<b>5</b>
<b>3</b>	Docking studies figures S1-S2	<b>6</b>
<b>4</b>	Docking studies figures S3-S4	<b>7</b>
<b>5</b>	Docking studies figures S5-S6	<b>8</b>
<b>6</b>	Docking studies figures S7-S8	<b>9</b>
<b>7</b>	Docking studies figures S9-S10	<b>10</b>
<b>8</b>	Docking studies figures S11-S12	<b>11</b>
<b>9</b>	Docking studies figures S13-S14	<b>12</b>
<b>10</b>	Docking studies figures S15-S16	<b>13</b>
<b>11</b>	Docking studies figures S17-S18	<b>14</b>
<b>12</b>	Docking studies figures S19-S20	<b>15</b>
<b>13</b>	Docking studies figures S21	<b>16</b>
<b>14</b>	<sup>1</sup> H-NMR and <sup>13</sup> C-NMR spectra of <i>N</i> -alkylated acridone analogues	<b>17</b>
<b>15</b>	<sup>1</sup> H-NMR and <sup>13</sup> C-NMR spectra of piperazine analogues	<b>27</b>
<b>16</b>	<sup>1</sup> H-NMR and <sup>13</sup> C-NMR spectra of analogues with tryptophan	<b>42</b>
<b>17</b>	LC/ESI-MS analysis for compounds <b>9a-i</b> and <b>10</b>	<b>58</b>
<b>18</b>	LC/ESI-MS analysis for compounds <b>S1</b> , <b>15a-d</b> , and <b>16a-h</b>	<b>69</b>
<b>19</b>	LC/ESI-MS analysis for compound <b>19</b>	<b>84</b>
<b>20</b>	LC/ESI-MS analysis for compound <b>23a</b>	<b>85</b>
<b>21</b>	LC/ESI-MS analysis for compound <b>23b</b>	<b>86</b>

<b>22</b>	LC/ESI-MS analysis for compound <b>23c</b>	<b>87</b>
<b>23</b>	LC/ESI-MS analysis for compounds <b>23d</b>	<b>88</b>
<b>24</b>	LC/ESI-MS analysis for compound <b>14</b>	<b>89</b>
<b>25</b>	LC/ESI-MS analysis for compound <b>20</b>	<b>91</b>

**Table S1. Docking scores and interactions between MARK4 and synthesized acridones.**


Compound	Binding score (Kcal/mol)	Hydrogen bonds	Other interacting residues
9a	-9.4	Ala135 (2.90 Å)	Ala83, Val70, Glu133, Val116, Met132, Ala195, Asn183, Glu182, Asp196, Gly63, Ile62, Gly138, Tyr134, Leu185
9b	-9.5	-	Ala135, Ala195, Ala83, Val116, Met132, Val70, Asp196, Lys85, Ala68, Lys69, Gly65, Gly63, Leu185, Glu139, Gly138, Ile62, Tyr134
9c	-10.0	Gly65 (3.09 Å)	Ala135, Ala195, Ala83, Glu133, Val116, Met132, Lys64, Gly63, Lys69, Lys85, Ala68, Val70, Asp196, Leu185, Glu139, Gly138, Ile62, Tyr134
9d	-9.5	Gly65 (3.08 Å)	Ala135, Ala195, Val116, Lys85, Ala83, Val70, Met132, Asp196, Ala68, Lys69, Lys64, Gly63, Leu185, Glu139, Gly138, Ile62, Tyr134
9e	-9.7	Gly65 (3.00 Å) Lys85 (3.07 Å)	Ala135, Ile62, Tyr134, Ala195, Ala83, Val116, Met132, Gly63, Val70, Ala68, Lys64, Lys69, Asp196, Lys85, Leu185, Glu139, Gly138
9f	-8.6	Ala135 (3.14 Å)	Ala135, Leu185, Gly138, Glu139, Glu182, Asn183, Asp196, Ala195, Val70, Val116, Ala83, Met132, Glu133, Lys85, Tyr134
9g	-9.5	-	Ala135, Leu185, Ala83, Glu133, Ala195, Val116, Met132, Gly63, Asp196, Lys64, Lys69, Gly65, Ala68, Lys85, Val70, Glu139, Gly138, Ile62, Tyr134
9h	-9.6	Gly65 (2.99 Å)	Ala135, Leu185, Ala83, Glu133, Ala195, Val116, Met132, Val70, Asp196, Lys69, Lys64, Ala68, Gly63, Glu139, Gly138, Ile62, Tyr134
9i	-9.9	Gly65 (3.08 Å)	Ala135, Ala195, Glu133, Ala83, Gly63, Met132, Val116, Lys85, Lys64, Asp196, Lys69, Ala68, Val70, Leu185, Glu139, Gly138, Ile62, Tyr134
10	-9.6	Ala135 (2.80 Å) Glu182 (2.01 Å) Asn183 (1.85 Å) Asp196 (2.75 Å)	Val70, Ala83, Glu133, Ala195, Met132, Val116, Gly63, Ile62, Gly138, Tyr134, Leu185
15a	-10.0	Ala135 (2.80 Å)	Val70, Ala83, Glu133, Val116, Ala195, Met132, Asn183, Glu182, Asp196, Gly65, Phe67, Ala68, Lys85, Gly63, Leu185, Ile62, Gly138, Tyr134
15b	-10.6	Ala135 (2.87 Å)	Ala83, Glu133, Val116, Val70, Ala195, Met132, Asn183, Glu182, Lys85, Ala68, Asn66, Gly65, Phe67, Ile87, Glu103, Gly198, Asp196, Gly63, Ile62, Leu185, Gly138, Tyr134
15c	-10.5	Ala135 (2.79 Å)	Ala83, Glu133, Val116, Val70, Ala195, Met132, Asn183, Glu182, Asp196, Lys85, Gly65, Ala68, Gly198, Glu103, Phe67, Gly63, Leu185, Ile62, Gly138, Tyr134
15d	-10.4	Ala135 (2.80 Å)	Ala83, Glu133, Val116, Val70, Ala195, Met132, Asn183, Glu182, Asp196, Lys85, Ala68, Gly65, Phe67, Gly198, Gly63, Leu185, Ile62, Gly138, Tyr134
15e	-10.3	Ala135 (2.80 Å)	Ala83, Glu133, Val116, Val70, Ala195, Met132, Asn183, Glu182, Asp196, Lys85, Gly65, Ala68, Phe67, Gly198, Gly63, Leu185, Ile62, Gly138, Tyr134
16a	-10.3	Ala135 (2.83 Å)	Val70, Glu133, Ala83, Leu185, Met132, Val116, Ala195, Gly63, Gly198, Asp178, Lys85, Glu182, Asp196, Tyr134, Gly138, Ile62
16c	-10.7	Ala135 (3.02 Å) Ala68 (3.66 Å)	Ala83, Val70, Glu133, Val116, Ala195, Gly63, Glu182, Asp196, Lys85, Phe67, Asn66, Ala68, Gly65, Ile62, Gly138, Tyr134, Leu185, Ala135
16b	-10.8	Ala135 (3.02 Å) Lys85 (3.24 Å)	Ala83, Glu133, Val116, Val70, Ala195, Gly63, Glu182, Gly198, Phe67, Gly65, Asn66, Asp196, Ala68, Ile62, Tyr134, Gly138, Leu185, Ala135
16d	-10.1	Ala135 (2.88 Å)	Val70, Ala83, Glu133, Val116, Ala195, Met132, Gly63, Gly65, Ala68, Glu182, Lys64, Asp196, Leu185, Gly138, Tyr134, Ile62
16e	-10.3	Ala135 (2.85 Å) Lys85 (3.36 Å) Asn66 (3.11 Å)	Ala83, Glu133, Ala195, Val116, Val70, Gly63, Met132, Ala68, Lys64, Gly65, Phe199, Asp178, Glu182, Asp196, Tyr134, Ile62, Gly138, Leu185
16f	-10.3	Ala135 (2.82 Å) Phe199 (3.38 Å)	Val70, Ala83, Glu133, Val116, Met132, Ala195, Gly63, Gly65, Lys64, Asp178, Gly198, Glu182, Asp196, Leu185, Tyr134, Gly138, Ile62
16g	-10.1	Ala135 (3.01 Å)	Ala83, Glu133, Val116, Ala195, Val70, Gly63, Glu182, Ala68, Gly65, Asn66, Phe67, Ser96, Leu92, Leu100, Ile87, Lys85, Asp196, Ile62, Gly138, Tyr134, Leu185, Ala135

**Table S1 (Continued). Docking scores and interactions between MARK4 and synthesized acridones.**


Compound	Binding score (Kcal/mol)	Hydrogen bonds	Other interacting residues
<b>16h</b>	-10.0	Ala135 (2.86 Å)	Val70, Ala83, Glu133, Val116, Ala195, Met132, Gly65, Ala68, Glu182, Asn183, Gly63, Asp196, Leu185, Gly138, Ile62, Tyr134
<b>20</b>	-9.9	Ala135 (3.80 Å) Asp196 (1.98 Å) Glu139 (2.62 Å)	Ala83, Glu133, Ala195, Val116, Glu182, Val70, Ala68, Lys85, Lys69, Gly65, Lys64, Glu139, Ile62, Gly63, Gly138, Tyr134, Leu185
<b>23a</b>	-10.5	Ala135 (2.85 Å) Asp196 (1.87 Å)	Ala83, Glu133, Val116, Met132, Ala195, Gly63, Glu139, Asp142, Lys64, Glu182, Gly138, Ala68, Lys85, Gly65, Lys69, Tyr134, Leu185, Ile62, Val70
<b>23b</b>	-10.6	Ala135 (2.80 Å) Asp196 (1.85 Å)	Leu185, Glu133, Ala83, Ala195, Met132, Val116, Glu182, Val70, Gly63, Lys85, Ala68, Lys69, Gly65, Lys64, Glu139, Asp142, Gly138, Tyr134, Ile62
<b>23c</b>	-10.3	Ala135 (2.87 Å) Asp196 (1.87 Å)	Ala83, Glu133, Val116, Met132, Ala195, Gly63, Glu139, Asp142, Lys64, Glu182, Gly138, Ala68, Lys85, Gly65, Lys69, Tyr134, Leu185, Ile62, Val70
<b>23d</b>	-10.4	Ala135 (2.85 Å) Asp196 (1.95 Å)	Ala83, Glu133, Val116, Met132, Ala195, Gly63, Glu139, Asp142, Ser136, Glu182, Lys64, Gly138, Ala68, Lys85, Gly65, Lys69, Leu185, Tyr134, Val70, Ile62, Ala135

**Table S2. Druglikeness of synthesized acridones.** (MW: Molecular Weight, MLogP: Lipophilicity, HBD: Hydrogen Bond Donor, HBA: Hydrogen Bond Acceptor, r.b.: rotatable bonds, TPSA: Topological Polar Surface Area)


Compound	MW (g/mol)	MLogP	HBD	HBA	r.b.	TPSA (Å <sup>2</sup> )	Druglikeness	
							Lipinski	Veber
<b>9a</b>	299.37	3.78	0	1	2	22.00	Yes (0 violations)	Yes (0 violations)
<b>9b</b>	313.39	3.99	0	1	2	22.00	Yes (0 violations)	Yes (0 violations)
<b>9c</b>	367.36	4.58	0	4	3	22.00	Yes (1 violation)	Yes (0 violations)
<b>9d</b>	317.36	4.15	0	2	2	22.00	Yes (1 violation)	Yes (0 violations)
<b>9e</b>	335.35	4.53	0	3	2	22.00	Yes (1 violation)	Yes (0 violations)
<b>9f</b>	263.33	3.31	0	1	2	22.00	Yes (0 violations)	Yes (0 violations)
<b>9g</b>	355.47	4.63	0	1	3	22.00	Yes (1 violation)	Yes (0 violations)
<b>9h</b>	324.38	3.04	0	2	2	45.79	Yes (0 violations)	Yes (0 violations)
<b>9i</b>	344.36	2.63	0	3	3	67.82	Yes (0 violations)	Yes (0 violations)
<b>10</b>	314.38	3.16	1	1	2	48.02	Yes (0 violations)	Yes (0 violations)
<b>15a</b>	425.52	2.81	0	3	5	45.55	Yes (0 violations)	Yes (0 violations)
<b>15b</b>	481.63	3.59	0	3	6	45.55	Yes (0 violations)	Yes (0 violations)
<b>15c</b>	470.52	1.83	0	5	6	91.37	Yes (0 violations)	Yes (0 violations)
<b>15d</b>	450.53	2.13	0	4	5	69.34	Yes (0 violations)	Yes (0 violations)
<b>15e</b>	443.51	3.18	0	4	5	45.55	Yes (0 violations)	Yes (0 violations)
<b>16a</b>	473.95	3.07	0	3	5	62.62	Yes (0 violations)	Yes (0 violations)
<b>16c</b>	457.50	2.97	0	4	5	62.62	Yes (0 violations)	Yes (0 violations)
<b>16b</b>	457.50	2.97	0	4	5	62.62	Yes (0 violations)	Yes (0 violations)
<b>16d</b>	484.50	1.65	0	5	6	108.44	Yes (0 violations)	Yes (0 violations)
<b>16e</b>	510.54	1.71	0	5	7	108.44	Yes (1 violation)	Yes (0 violations)
<b>16f</b>	508.40	3.53	0	3	5	62.62	Yes (1 violation)	Yes (0 violations)
<b>16g</b>	575.50	4.10	0	9	7	62.62	Yes (1 violation)	Yes (0 violations)
<b>16h</b>	429.47	1.43	0	4	5	75.76	Yes (0 violations)	Yes (0 violations)
<b>20</b>	453.49	2.07	3	4	7	104.19	Yes (0 violations)	Yes (0 violations)
<b>23a</b>	542.63	3.07	3	3	9	95.99	Yes (1 violation)	Yes (0 violations)
<b>23b</b>	546.59	3.25	3	4	9	95.99	Yes (1 violation)	Yes (0 violations)
<b>23c</b>	563.05	3.34	3	3	9	95.99	Yes (1 violation)	Yes (0 violations)
<b>23d</b>	600.66	2.88	3	5	12	122.29	Yes (1 violation)	No (1 violation)




**Figure S1.** (A) 2D molecular docking model of compound **9b** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **9b** in the active site of MARK4 (BIOVIA Discovery Studio).





**Figure S2.** (A) 2D molecular docking model of compound **9c** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **9c** in the active site of MARK4 (BIOVIA Discovery Studio).





**Figure S3.** (A) 2D molecular docking model of compound **9e** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **9e** in the active site of MARK4 (BIOVIA Discovery Studio).





**Figure S4.** (A) 2D molecular docking model of compound **9f** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **9f** in the active site of MARK4 (BIOVIA Discovery Studio).

**A)****B)**



**Figure S5.** **(A)** 2D molecular docking model of compound **9g** in the active site of MARK4 (PDB code: 5ES1). **(B)** 3D model of the interaction between compound **9g** in the active site of MARK4 (BIOVIA Discovery Studio).

**A)****B)**


**Figure S6.** **(A)** 2D molecular docking model of compound **9h** in the active site of MARK4 (PDB code: 5ES1). **(B)** 3D model of the interaction between compound **9h** in the active site of MARK4 (BIOVIA Discovery Studio).

**A)****B)**


**Figure S7.** **(A)** 2D molecular docking model of compound **9i** in the active site of MARK4 (PDB code: 5ES1). **(B)** 3D model of the interaction between compound **9i** in the active site of MARK4 (BIOVIA Discovery Studio).

**A)****B)**



**Figure S8.** **(A)** 2D molecular docking model of compound **15a** in the active site of MARK4 (PDB code: 5ES1). **(B)** 3D model of the interaction between compound **15a** in the active site of MARK4 (BIOVIA Discovery Studio).





**Figure S9.** (A) 2D molecular docking model of compound **15b** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **15b** in the active site of MARK4 (BIOVIA Discovery Studio).





**Figure S10.** (A) 2D molecular docking model of compound **15c** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **15c** in the active site of MARK4 (BIOVIA Discovery Studio).

**A)****B)**



**Figure S11.** (A) 2D molecular docking model of compound **15d** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **15d** in the active site of MARK4 (BIOVIA Discovery Studio).

**A)****B)**


**Figure S12.** (A) 2D molecular docking model of compound **15e** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **15e** in the active site of MARK4 (BIOVIA Discovery Studio).

**A)****B)**


**Figure S13.** (A) 2D molecular docking model of compound **16c** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **16c** in the active site of MARK4 (BIOVIA Discovery Studio).

**A)****B)**


**Figure S14.** (A) 2D molecular docking model of compound **16d** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **16d** in the active site of MARK4 (BIOVIA Discovery Studio).




**Figure S15.** (A) 2D molecular docking model of compound **16e** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **16e** in the active site of MARK4 (BIOVIA Discovery Studio).





**Figure S16.** (A) 2D molecular docking model of compound **16f** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **16f** in the active site of MARK4 (BIOVIA Discovery Studio).





**Figure S17.** (A) 2D molecular docking model of compound **16g** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **16g** in the active site of MARK4 (BIOVIA Discovery Studio).





**Figure S18.** (A) 2D molecular docking model of compound **16h** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **16h** in the active site of MARK4 (BIOVIA Discovery Studio).

**A)****B)**

**Figure S19.** (A) 2D molecular docking model of compound **20** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **20** in the active site of MARK4 (BIOVIA Discovery Studio).



**A)****B)**

**Figure S20.** (A) 2D molecular docking model of compound **23b** in the active site of MARK4 (PDB code: 5ES1). (B) 3D model of the interaction between compound **23b** in the active site of MARK4 (BIOVIA Discovery Studio).



**A)****B)**

**Figure S21.** **(A)** 2D molecular docking model of compound **23d** in the active site of MARK4 (PDB code: 5ES1). **(B)** 3D model of the interaction between compound **23d** in the active site of MARK4 (BIOVIA Discovery Studio).


acr04




acr04 carbon




acr05




acr05 carbon




acr07




acr07 carbon




acr08




acr08 carbon




acr09




acr09 carbon




acr10




acr10 carbon




acr13




acr13 carbon





acrl4





acrl4 carbon




acr15




acr15 carbon




acr16




acr16 carbon




mv61




mv61 carbon




mv62 TFA salt




mv62 TFA salt carbon




mv141




mv141 carbon




mv142




mv142 carbon




mv143




mv143 carbon




mv144




mv144 carbon




mv145




mv145 carbon




mv130




mv130 carbon




mv126




mv126 carbon




mv131




mv131 carbon




mv133




mv133 carbon




mv132




mv132 carbon




mv134




mv134 carbon




mv136




mv136 carbon




mv135






mv135 carbon




mv20









mv23




mv23 carbon




mv24




mv24 carbon




mv29




mv29carbon




mv27




mv27 carbon





mv147




mv147 carbon











mv35 HCl salt<sup>14</sup>  
— 11.07





mv35 HCl salt carbon












mv54




mv54 carbon




mv56




mv56 carbon



mv153



mv153 carbon



Analytical method for compounds **9a-i** and **10**:

LC-MS/HPLC: LC-20AD Shimadzu connected to Shimadzu LCMS-2010EV

Mobile Phase A: 0.1% FA in water

Mobile Phase B: methanol

HPLC column: Poroshell 120 EC-C18, 4.6 x 100 mm, 2.7 µm

Flow rate: 0.4 mL/min

Run time: 20 min




Column temperature: 26°C

UV detector: 254 nm




MS detector: 1.65 kV

LC isocratic:




Time (min)	Mobile Phase A (%)	Mobile Phase B (%)
0	0	100
20	0	100






ESI-MS, positive mode: m/z calcd mass for  $C_{22}H_{21}NO_2Na$   $[M + MeOH + Na]^+ = 454.15$ ; found 353.90.






ESI-MS, positive mode: m/z calcd mass for C<sub>23</sub>H<sub>23</sub>NO<sub>2</sub>Na [M + MeOH + Na]<sup>+</sup> = 368.16; found 367.90.






ESI-MS, positive mode: m/z calcd mass for  $C_{23}H_{20}F_3NO_2Na$   $[M + MeOH + Na]^+ = 422.13$ ; found 421.90.






ESI-MS, positive mode: m/z calcd mass for  $C_{22}H_{20}FNO_2Na$   $[M + MeOH + Na]^+ = 372.14$ ; found 371.90.






ESI-MS, positive mode: m/z calcd mass for C<sub>22</sub>H<sub>19</sub>F<sub>2</sub>NO<sub>2</sub>Na [M + MeOH + Na]<sup>+</sup> = 390.13; found 389.85.






ESI-MS, positive mode: m/z calcd mass for  $C_{19}H_{21}NO_2Na$   $[M + MeOH + Na]^+$  = 318.15; found 317.90.






ESI-MS, positive mode: m/z calcd mass for C<sub>26</sub>H<sub>29</sub>NO<sub>2</sub>Na [M + MeOH + Na]<sup>+</sup> = 410.21; found 409.90.



ESI-MS, positive mode: m/z calcd mass for  $C_{23}H_{20}N_2O_2Na$   $[M + MeOH + Na]^+ = 379.14$ ; found 378.85.



ESI-MS, positive mode: m/z calcd mass for  $C_{22}H_{20}N_2O_4Na$   $[M + MeOH + Na]^+ = 399.13$ ; found 398.90.



ESI-MS, positive mode:  $m/z$  calcd mass for  $C_{22}H_{22}N_2O_2Na$   $[M + MeOH + Na]^+ = 369.16$ ; found 368.85.

Analytical method for compounds **S1**, **15a-d** and **16a-h**:

LC-MS/HPLC: LC-20AD Shimadzu connected to Shimadzu LCMS-2010EV

Mobile Phase A: 0.1% FA in water

Mobile Phase B: methanol

HPLC column: SUPELCO Discovery C18 25 cm x 4.6 mm, 5 µm

Flow rate: 0.4 mL/min

Run time: 20 min




Column temperature: 26°C

UV detector: 254 nm




MS detector: 1.65 kV

LC isocratic:




Time (min)	Mobile Phase A (%)	Mobile Phase B (%)
0	0	100
20	0	100






ESI-MS, positive mode: m/z calcd mass for  $C_{25}H_{29}N_3O_4Na$   $[M + Na]^+ = 458.20$ ; found 457.90.






ESI-MS, positive mode: m/z calcd mass for  $C_{27}H_{28}N_3O_2 [M + H]^+$  = 426.22; found 426.10.






ESI-MS, positive mode: m/z calcd mass for  $C_{31}H_{36}N_3O_2 [M + H]^+$  = 482.28; found 482.10.






ESI-MS, positive mode:  $m/z$  calcd mass for  $C_{27}H_{27}N_4O_4 [M + H]^+$  = 471.20; found 471.00.






ESI-MS, positive mode: m/z calcd mass for  $C_{28}H_{26}N_4O_2Na$   $[M + Na]^+ = 473.19$ ; found 472.95.






ESI-MS, positive mode:  $m/z$  calcd mass for  $C_{27}H_{27}FN_3O_2 [M + H]^+$  = 444.21; found 441.95.






ESI-MS, positive mode:  $m/z$  calcd mass for  $\text{C}_{27}\text{H}_{24}\text{ClN}_3\text{O}_3\text{Na} [\text{M} + \text{Na}]^+ = 496.14$ ; found 495.85.






ESI-MS, positive mode: m/z calcd mass for  $C_{27}H_{24}FN_3O_3Na$   $[M + Na]^+ = 480.17$ ; found 479.90.






ESI-MS, positive mode: m/z calcd mass for  $C_{27}H_{24}FN_3O_3Na$   $[M + Na]^+ = 480.17$ ; found 479.95.






ESI-MS, positive mode: m/z calcd mass for  $C_{27}H_{23}Cl_2N_3O_3Na$   $[M + Na]^+ = 530.10$ ; found 529.80.






ESI-MS, positive mode:  $m/z$  calcd mass for  $C_{29}H_{23}F_6N_3O_3Na$   $[M + Na]^+ = 598.15$ ; found 597.80.






ESI-MS, positive mode: m/z calcd mass for  $C_{27}H_{24}N_4O_5Na$   $[M + Na]^+ = 507.16$ ; found 507.00.






ESI-MS, positive mode: m/z calcd mass for  $C_{29}H_{26}N_4O_5Na$   $[M + Na]^+ = 533.18$ ; found 532.90.






ESI-MS, positive mode: m/z calcd mass for  $C_{25}H_{23}N_3O_4Na$   $[M + Na]^+$  = 452.16; found 451.90.






ESI-MS, positive mode: m/z calcd mass for C<sub>28</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub>Na [M + Na]<sup>+</sup> = 490.17; found 490.05.






ESI-MS, positive mode: *m/z* calcd mass for  $C_{34}H_{30}N_4O_3Na$   $[M + Na]^+ = 565.22$ ; found 564.90.



ESI-MS, positive mode: m/z calcd mass for  $C_{33}H_{27}FN_4O_3Na$   $[M + Na]^+$  = 569.20; found 568.95.



ESI-MS, positive mode: m/z calcd mass for  $C_{33}H_{27}ClN_4O_3Na$   $[M + Na]^+ = 585.17$ ; found 584.85.



ESI-MS, positive mode: m/z calcd mass for  $C_{36}H_{32}N_4O_5Na$   $[M + Na]^+$  = 623.22; found 622.80.

Analytical method for compounds **14** and **20**:

LC-MS/HPLC: LC-20AD Shimadzu connected to Shimadzu LCMS-2010EV

Mobile Phase A: 0.1% FA in water

Mobile Phase B: 0.1% FA in acetonitrile

HPLC column: Poroshell 120 EC-C18, 4.6 x 100 mm, 2.7 µm

Flow rate: 0.4 mL/min

Run time: 40 min




Column temperature: 26°C

UV detector: 254 nm




MS detector: 1.65 kV

LC isocratic:

Time (min)	Mobile Phase A (%)	Mobile Phase B (%)
0	90	10
30	10	90
32	10	90
35	10	90
40	90	10



ESI-MS, positive mode:  $m/z$  calcd mass for  $\text{C}_{20}\text{H}_{22}\text{N}_3\text{O}_2$   $[\text{M} + \text{H}]^+ = 336.17$ ; found 335.90.



ESI-MS, positive mode:  $m/z$  calcd mass for  $C_{27}H_{24}N_3O_4 [M + H]^+ = 454.17$ ; found 453.95.